Researchers have found genomic, transcriptomic, proteomic, and phenotypic variation in a comparison of HeLa cells across laboratories and over time.
Ireland-based Luxcel is a developer of real-time fluorescence plate reader-based in vitro cell assay kits.
The grant is being provided under the European Commission's Horizon 2020 Research and Innovation Framework program.
Harvard Bioscience will offer Fluxion's BioFlux and IonFlux cellular analysis platforms to its North American customers.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
NEW YORK (GenomeWeb News) – The University Medical Center at Johannes Gutenberg University Mainz in Germany (JGU) announced today separate deals to build out its capabilities in neuroscience research.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.
NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.
CNBC reports that there are thousands of genetic tests available for consumers to chose between.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.